Nath Bio-Genes Complete Financial Statements
In FY2026, Nath Bio-Genes (NATHBIOGEN) reported revenue ₹55 Cr, net profit ₹0 Cr and EPS ₹-0.79. Full financial statements from FY2022 to FY2026 (5 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see NATHBIOGEN screener.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
NATHBIOGEN Revenue, Net Profit & EBITDA — Year-on-Year Growth
NATHBIOGEN YoY (Mar 2025 vs Mar 2026) — revenue -1.8%, net profit -100.0%, EBITDA +60.0%, expenses -9.6%. Explore NATHBIOGEN true value to estimate fundamental worth using multiple valuation models.
NATHBIOGEN Income Statement — Revenue, EBITDA & Net Profit
Nath Bio-Genes revenue ₹55 Cr, EBITDA ₹8 Cr, net profit ₹0 Cr, EPS ₹-0.79 (2026). Review NATHBIOGEN earnings valuation to evaluate earnings-based valuation against sector peers.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 55 | 48 | 56 | 288 | 70 | 32 | 44 | 244 | 37 | 23 | 45 | 235 | 34 | 22 | 28 | 209 | 25 |
| Expenses | 47 | 38 | 52 | 245 | 62 | 27 | 39 | 207 | 29 | 18 | 41 | 198 | 26 | 17 | 137 | 175 | 20 |
| EBITDA | 8 | 10 | 5 | 42 | 8 | 5 | 5 | 37 | 9 | 5 | 4 | 37 | 8 | 5 | -109 | 35 | 6 |
| Operating Profit Margin % | 9.00% | 14.00% | 1.00% | 13.00% | 5.00% | 15.00% | 9.00% | 15.00% | 22.00% | 22.00% | 9.00% | 16.00% | 18.00% | 22.00% | -405.00% | 16.00% | 22.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 5 | 4 | 1 | 3 | 5 | 3 | 1 | 2 | 4 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit Before Tax | 3 | 6 | 2 | 38 | 3 | 1 | 3 | 34 | 4 | 2 | 2 | 34 | 5 | 2 | -113 | 31 | 2 |
| Tax | 3 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 4 | 0 | 1 |
| Net Profit | 0 | 5 | 2 | 37 | 2 | 1 | 3 | 33 | 3 | 2 | 1 | 33 | 4 | 2 | -116 | 31 | 1 |
| Earnings Per Share (₹) | -0.79 | 2.53 | 0.42 | 19.58 | 0.89 | 0.53 | 1.87 | 17.49 | 1.33 | 0.86 | 0.77 | 17.59 | 2.02 | 0.77 | -61.22 | 16.18 | 0.71 |
NATHBIOGEN Balance Sheet — Assets, Liabilities & Shareholders' Equity
NATHBIOGEN total assets ₹1,026 Cr, total equity ₹644 Cr, total liabilities ₹ Cr (2025).
| Particulars | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| Total Assets | 1,026 | 880 | 793 | 740 |
| Current Assets | 690 | 572 | 521 | 468 |
| Fixed Assets | 250 | 250 | 244 | 245 |
| Capital Work in Progress | 0 | 0 | 0 | 0 |
| Investments | 6 | 6 | 5 | 5 |
| Other Assets | 770 | 625 | 543 | 490 |
| LIABILITIES | ||||
| Total Liabilities | ||||
| Current Liabilities | 17 | 8 | 3 | 3 |
| Non-Current Liabilities | ||||
| SHAREHOLDERS' EQUITY | ||||
| Total Equity | 644 | 610 | 573 | 542 |
| Share Capital | 19 | 19 | 19 | 19 |
| Reserves & Surplus | 625 | 591 | 554 | 523 |
NATHBIOGEN Cash Flow Statement — Operating, Investing & Financing
Nath Bio-Genes operating cash flow ₹18 Cr, investing ₹-4 Cr, financing ₹-2 Cr, net cash flow ₹12 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 |
|---|---|---|---|---|
| Operating Activities | 18 | 75 | 38 | 17 |
| Investing Activities | -4 | -27 | -3 | -20 |
| Financing Activities | -2 | -8 | -2 | -22 |
| Net Cash Flow | 12 | 39 | 34 | -25 |